Received May 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9G523 | — |
an adult patient received a pediatric dose; an adult patient received a pediatric dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 63-year-old female patient who received HBV (Engerix B pediatric) (batch number 9G523, expiry date 20-MAY-2027) for prophylaxis. On 15-APR-2026, the patient received Engerix B pediatric. On 15-APR-2026, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: an adult patient received a pediatric dose) and underdose (Verbatim: an adult patient received a pediatric dose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.